Literature DB >> 7734324

Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status.

A H McCann1, A Kirley, D N Carney, N Corbally, H M Magee, G Keating, P A Dervan.   

Abstract

The present study reports on the frequency of MDM2 gene amplification and MDM2 protein expression in a series of 100 breast carcinomas and its association with accumulation of the p53 protein. Of the 100 cases, frozen samples for 82 cases were available for Southern blotting. Three of the 82 (4%) demonstrated MDM2 gene amplification of up to 6-fold. Immunohistochemical analysis of the formalin-fixed, paraffin-embedded tumours demonstrated that 7/97 (7%) had nuclear expression for MDM2 in 10-50% of the tumour cells (type 2 staining) and were denoted MDM2+. Two of the MDM2-amplified samples were MDM2+ with one of the two tumours also displaying type 2 p53 nuclear staining. Finally at the protein level, MDM2+ tumours were significantly associated with tumours having low levels of p53 staining (0-10% cells positive) (P = 0.03). We conclude that MDM2 gene amplification occurs at a lower frequency in breast cancer than in non-epithelial tumours. Alterations in MDM2 and p53 may represent alternative pathways in tumorigenesis, but they are not mutually exclusive in all cases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7734324      PMCID: PMC2033791          DOI: 10.1038/bjc.1995.189

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

2.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections.

Authors:  S R Shi; M E Key; K L Kalra
Journal:  J Histochem Cytochem       Date:  1991-06       Impact factor: 2.479

3.  No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families.

Authors:  W Warren; R A Eeles; B A Ponder; D F Easton; D Averill; M A Ponder; K Anderson; A M Evans; R DeMars; R Love
Journal:  Oncogene       Date:  1992-05       Impact factor: 9.867

4.  Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line.

Authors:  L Cahilly-Snyder; T Yang-Feng; U Francke; D L George
Journal:  Somat Cell Mol Genet       Date:  1987-05

5.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

6.  Abnormal expression of wild type p53 protein in normal cells of a cancer family patient.

Authors:  D M Barnes; A M Hanby; C E Gillett; S Mohammed; S Hodgson; L G Bobrow; I M Leigh; T Purkis; C MacGeoch; N K Spurr
Journal:  Lancet       Date:  1992-08-01       Impact factor: 79.321

7.  p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix.

Authors:  T D Kessis; R J Slebos; S M Han; K Shah; X F Bosch; N Muñoz; L Hedrick; K R Cho
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

8.  MDM2 gene amplification in metastatic osteosarcoma.

Authors:  M Ladanyi; C Cha; R Lewis; S C Jhanwar; A G Huvos; J H Healey
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

9.  Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

Authors:  S S Fakharzadeh; S P Trusko; D L George
Journal:  EMBO J       Date:  1991-06       Impact factor: 11.598

10.  Mutations in p53 do not account for heritable breast cancer: a study in five affected families.

Authors:  J Prosser; P A Elder; A Condie; I MacFadyen; C M Steel; H J Evans
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

View more
  28 in total

Review 1.  MDM2 and mitochondrial function: One complex intersection.

Authors:  Camila Rubio-Patiño; Andrew Paul Trotta; Jerry Edward Chipuk
Journal:  Biochem Pharmacol       Date:  2018-11-01       Impact factor: 5.858

2.  p53-dependent ceramide response to genotoxic stress.

Authors:  G S Dbaibo; M Y Pushkareva; R A Rachid; N Alter; M J Smyth; L M Obeid; Y A Hannun
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

3.  Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.

Authors:  Moqin Qiu; Yingchun Liu; Xiangyuan Yu; Linyuan Qin; Chunhua Bei; Xiaoyun Zeng; Xiaoqiang Qiu; Bo Tang; Songqing He; Hongping Yu
Journal:  Tumour Biol       Date:  2015-10-17

4.  MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation.

Authors:  Jer-Yen Yang; Cong S Zong; Weiya Xia; Yongkun Wei; Mohamed Ali-Seyed; Zheng Li; Kristine Broglio; Donald A Berry; Mien-Chie Hung
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

Review 5.  P53, apoptosis, and breast cancer.

Authors:  D M Barnes; R S Camplejohn
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

6.  Alterations of the Notch pathway in lung cancer.

Authors:  Britta Westhoff; Ivan N Colaluca; Giovanni D'Ario; Maddalena Donzelli; Daniela Tosoni; Sara Volorio; Giuseppe Pelosi; Lorenzo Spaggiari; Giovanni Mazzarol; Giuseppe Viale; Salvatore Pece; Pier Paolo Di Fiore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

Review 7.  The Role of MDM2 Amplification and Overexpression in Tumorigenesis.

Authors:  Jonathan D Oliner; Anne Y Saiki; Sean Caenepeel
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

8.  Progesterone inhibition of MDM2 p90 protein in MCF-7 human breast cancer cell line is dependent on p53 levels.

Authors:  Moussa Alkhalaf; Abdalla M El-Mowafy; Laila A Abou-Zeid
Journal:  J Mol Genet Med       Date:  2005-08-19

9.  Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.

Authors:  Gopa Iyer; Hikmat Al-Ahmadie; Nikolaus Schultz; Aphrothiti J Hanrahan; Irina Ostrovnaya; Arjun V Balar; Philip H Kim; Oscar Lin; Nils Weinhold; Chris Sander; Emily C Zabor; Manickam Janakiraman; Ilana R Garcia-Grossman; Adriana Heguy; Agnes Viale; Bernard H Bochner; Victor E Reuter; Dean F Bajorin; Matthew I Milowsky; Barry S Taylor; David B Solit
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

10.  Interferon-inducible protein IFIXalpha1 functions as a negative regulator of HDM2.

Authors:  Yi Ding; Jin-Fong Lee; Hua Lu; Mong-Hong Lee; Duen-Hwa Yan
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.